Insider Selling: Alkermes Plc (ALKS) Director Sells 1,000 Shares of Stock
Alkermes Plc (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $54.99, for a total transaction of $54,990.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $494,910. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Alkermes Plc (NASDAQ ALKS) traded up $0.66 during mid-day trading on Wednesday, hitting $55.88. 501,181 shares of the stock were exchanged, compared to its average volume of 542,800. Alkermes Plc has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. The firm has a market capitalization of $8,590.00, a P/E ratio of -50.34 and a beta of 2.13.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The business had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same quarter last year, the company earned ($0.09) earnings per share. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. research analysts forecast that Alkermes Plc will post -0.59 EPS for the current fiscal year.
Several analysts have issued reports on ALKS shares. UBS Group set a $54.00 price objective on shares of Alkermes and gave the company a “hold” rating in a research report on Friday, October 27th. Mizuho set a $81.00 price objective on shares of Alkermes and gave the company a “buy” rating in a research report on Saturday, October 21st. Credit Suisse Group set a $66.00 price objective on shares of Alkermes and gave the company a “buy” rating in a research report on Tuesday, November 28th. BidaskClub raised shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Alkermes has an average rating of “Hold” and a consensus target price of $63.55.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.